Parallel Detection of Multiple Biomarkers During Spaceflight, Phase I

Maintaining the health of astronauts during extended spaceflight is critical to the success of the mission. Radiation Monitoring Devices, Inc. (RMD) proposes an instrument to monitor astronauts' physiological responses to stress, microgravity, radiation, infection, and pharmaceutical agents through detection of multiple biological markers. This will be accomplished under conditions of microgravity, within the weight, size and power requirements of space missions, and with minimal human intervention. One representative biomarker of interest is 8-oxo-dG that serves as an indicator of oxidative DNA damage from radiation, chemicals, inflammation, and by-products of metabolism. Upon repair of the damaged DNA, 8-oxo-dG is excreted into the urine where it may be conveniently monitored. However, serious obstacles to detection and quantification arise due to the low amounts present and the complex chemical composition of urine. Current techniques suffer from at least one of the following shortcomings: they are slow and labor-intensive, require complex instrumentation and a highly-trained operator, cannot be easily multiplexed to monitor many analytes, consume large amounts of reagents, and are not compatible for use under microgravity. We will overcome these limitations by incorporating all analytical steps into a single microfluidic chip. Our system will utilize affinity purification and electrochemical detection.

This is a mature technology (TRL 7+) — the realistic path in is usually NASA's Technology Transfer Program: licensing an existing NASA patent, or a Space Act Agreement to use NASA facilities/expertise directly. NASA also runs a startup licensing program with no upfront fee for companies formed to commercialize a specific NASA technology.

None of these are guaranteed paths for this specific project — TechPort itself doesn't have an "apply" button. Reaching out to the contact(s) above with a specific question is usually the fastest way to find out what's actually open.